The Official Website of the Acid Maltase Deficiency Association

It is difficult to say what is impossible for the dreams of yesterday are the hopes of today and the reality of tomorrow. - Robert H. Goddard

MTAP Fact Sheet June 2007

Posted on: June 27, 2007

MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a larger scale manufacturing process for a limited time until this manufacturing scale is approved by the FDA.  Patients enrolled in MTAP will be provided Myozyme at no cost during the course of the program.  The goals of MTAP are two-fold:  (a) to minimize any potential disruption in the treatment of patients already on therapy; and (b) to ensure that Myozyme is available for new patients who are in the most urgent clinical need. 

Download complete article

Disclaimer: The AMDA does not endorse any of the products, medications, treatments or information reported herein. The website and its contents is intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.

Address: AMDA PO Box 700248
San Antonio, Texas 78270 USA